JUL 2026 · FINANCING
Pre-A financing completed
The financing supports BR101 development and continued investment in Byterna’s personalized cancer-vaccine and programmable mRNA capabilities.
Byterna announced the completion of a Pre-A financing round with continued investment from Efung Capital and strategic participation from Insilico Medicine.
The company stated that proceeds would support BR101, its personalized circular mRNA cancer-vaccine pipeline and continued development of an AI-enabled mRNA R&D system.